1. PI3K/Akt/mTOR
  2. MELK

OTSSP167 (Synonyms: MELK inhibitor)

Cat. No.: HY-15512
Handling Instructions

OTSSP167 is a highly potent MELK inhibitor with IC50 value of 0.41 nM.

For research use only. We do not sell to patients.
OTSSP167 Chemical Structure

OTSSP167 Chemical Structure

CAS No. : 1431697-89-0

Size Price Stock
5 mg USD 180 Get quote
10 mg USD 288 Get quote
50 mg USD 900 Get quote

* Please select Quantity before adding items.

Other In-stock Forms of OTSSP167:

Other Forms of OTSSP167:

    OTSSP167 purchased from MCE. Usage Cited in: Mol Cancer. 2014 May 4;13:100.

    MELK specific inhibitor OTSSP167 suppresses cell migration and invasion. A, Immunoblotting representing MELK expression in SGC7901 cell following OTSSP167 treatment for indicated period. In the upper panel, SGC7901 cell are treated with different concentration (0, 0.1, 1 μM) of OTSSP167 for 1 h and 2 h. In the lower panel, SGC7901/vector and SGC7901/MELK cell are treated with 1 μM OTSSP167 for 2 h. C, SGC7901/vector and SGC7901/MELK cells are treated with 1 μM OTSSP167 for indicated period and

    OTSSP167 purchased from MCE. Usage Cited in: Sci Rep. 2017 Feb 14;7:42502.

    In vitro kinase assays are performed using MPK38 immunoprecipitates, which are obtained from cell lysates of wild-type and clonal CRISPR/Cas9 ZPR9 (T252A) KI isolates, treated with (+) or without (−) OTSSP167 (1 μM, 2 h), a MPK38-specific inhibitor, in the presence of ZPR9 immunoprecipitates as the substrate. Recombinant MPK38 proteins (lower panels), which were expressed in bacterial cells, treated with (+) or without (−) OTSSP167 are also used instead of the MPK38 immunoprecipitates (upper pan

    OTSSP167 purchased from MCE. Usage Cited in: Gynecol Oncol. 2017 Apr;145(1):159-166.

    Western blotting demonstrates that 100 nM OTSSP167 for 48 h produces marked PARP-1 cleavage in HGSOC cell lines whereas no or weak PARP-1 cleavage is observed in normal ovarian surface epithelial cells (HOSE6-3) and in the fallopian tubal cells (FT33-tag, FT190, FT237).

    OTSSP167 purchased from MCE. Usage Cited in: PLoS One. 2017 Feb 24;12(2):e0172832.

    OTS167 reduces proliferation and regulates MELK transcript but not protein levels in TNBC cells. The MELK 52 kDa variant is highly expressed in the TNBC cell lines but not in luminal A MCF-7.

    OTSSP167 purchased from MCE. Usage Cited in: EMBO Mol Med. 2018 Feb 5. pii: e8274.

    Validation of effects of OTS167 on phosphorylation of p90RSK and its targets. C4-2b cells are treated with vehicle or 30 nM OTS167 for the indicated times, and levels of total and phosphorylated proteins are determined by Western blot analysis. β-Actin is used as a loading control.

    Featured Recommendations

    • Biological Activity

    • Protocol

    • Technical Information

    • References


    OTSSP167 is a highly potent MELK inhibitor with IC50 value of 0.41 nM.

    IC50 & Target

    IC50: 0.41 nM (MELK)

    In Vitro

    OTSSP167 inhibits the growth of A549 (lung), T47D (breast), DU4475 (breast), 22Rv1 (prostate) and HT1197 (bladder) cancer cells with IC50 values of 6.7, 4.3, 2.3, 6.0 and 97 nM, respectively[1]. OTSSP167 can abrogate the mitotic checkpoint, disrupt MCC and MCC-APC/C interaction in MCF7 cells. OTSSP167 causes GFP-MELK localization to cell cortex in prometaphase cells[2]. OTSSP167 is a MELK selective inhibitor, exhibits a strong in vitro activity, conferring an IC50 of 0.41 nM[3].

    In Vivo

    OTSSP167 (20 mg/kg, i.v.) results in tumor growth inhibition (TGI) of 73% in xenograft mouse model; OTSSP167 (1, 5, and 10 mg/kg, p.o.) reveals TGI of 51, 91, and 108%, respectively. OTSSP167 (20 mg/kg, p.o.) shows no tumor growth suppressive effect on PC-14 xenografts[1].

    Preparing Stock Solutions
    Concentration Volume Mass 1 mg 5 mg 10 mg
    1 mM 2.0516 mL 10.2581 mL 20.5162 mL
    5 mM 0.4103 mL 2.0516 mL 4.1032 mL
    10 mM 0.2052 mL 1.0258 mL 2.0516 mL
    Please refer to the solubility information to select the appropriate solvent.
    Kinase Assay

    For in vitro kinase assay, MELK recombinant protein (0.4 μg) is mixed with 5 μg of each substrate in 20 μL of kinase buffer containing 30 mM Tris-HCl (pH), 10 mM DTT, 40 mM NaF, 10 mM MgCl2, 0.1 mM EGTA with 50 μM cold-ATP and 10 Ci of [γ-32P]ATP for 30 min at 30°C. The reaction Is terminated by addition of SDS sample buffer and boiled for 5 min prior to SDS-PAGE. The gel is dried and autoradiographed with intensifying screens at room temperature. OTSSP167 (final concentration of 10 nM) is dissolved in DMSO and added to kinase buffer before the incubation. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Cell Assay

    OTSSP167 is dissolved in DMSO.

    In vitro cell viability is measured by the colorimetric assay using Cell Counting Kit-8. Cells are plated in 100 μL in 96-well plates at a density that generates continual linear growth (A549, 1×103 cells; T47D, 3×103 cells; DU4475, 4×103 cells; 22Rv1, 6×103 cells; and HT1197, 2×103 cells, in 100 μL per well). The cells are allowed to adhere overnight before exposure to OTSSP167 for 72 hours at 37°C. Plates are read using a spectrophotometer at a wavelength of 450 nm. All assays are carried out in triplicate. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Administration

    OTSSP167 is prepared in a vehicle of 0.5% methylcellulose for oral administration, or formulated in 5% glucose for intravenous administration.

    MDA-MB-231 cells are injected into the mammary fat pads of NOD.CB17-Prkdcscid/J mice. A549, MIAPaCa-2 and PC-14 cells (1×105 cells) are injected subcutaneously in the left flank of female BALB/cSLC-nu/nu mice. DU145 cells are injected subcutaneously in the left flank of male BALB/cSLC-nu/nu mice. When MDA-MB-231, A549, DU145, MIAPaCa-2, and PC-14 xenografts has reached an average volume of 100, 210, 110, 250, and 250 mm3, respectively, animals are randomized into groups of 6 mice (except for PC-14, for which groups of 3 mice are used). For oral administration, OTSSP167 and other compounds are prepared in a vehicle of 0.5% methylcellulose and given by oral garbage at the indicated dose and schedule. For intravenous administration, compounds are formulated in 5% glucose and injected into the tail vein. An administration volume of 10 mL per kg of body weight is used for both administration routes. Tumor volumes are determined every other day using a caliper. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Molecular Weight




    CAS No.



    ClC1=CC(C2=CC=C(N=CC(C(C)=O)=C3N[[email protected]]4CC[[email protected]](CN(C)C)CC4)C3=N2)=CC(Cl)=C1O


    Please store the product under the recommended conditions in the Certificate of Analysis.


    Room temperature in continental US; may vary elsewhere

    Solvent & Solubility

    10 mM in DMSO

    OTSSP167 is prepared in vehicle (PBS)[4].

    * "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.


    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product name



    Applicant name *


    Email address *

    Phone number *


    Organization name *

    Country *


    Requested quantity *


    Bulk Inquiry

    Inquiry Information

    Product Name:
    Cat. No.: